Deals & Corporate Governance

  • June 24, 2025

    A Midyear Review: Healthcare Dealmaking Trends Of 2025

    Law360 Healthcare Authority reviews key trends that helped shape dealmaking activity in the healthcare industry so far this year.

  • June 24, 2025

    Goodwin Procter Adds PE Firm General Counsel In NY

    Goodwin Procter LLP has added the former general counsel of private equity firm Gurnet Point Capital to bolster its life sciences and healthcare practice groups.

  • June 23, 2025

    Teladoc Says Investor Suit Over User Losses Is 'Illogical'

    Telemedicine giant Teladoc Health Inc. and two of its executives seek to shed a proposed investor class action, telling a New York federal judge the shareholder suit makes "illogical" claims that they lied about post-pandemic increases in customer acquisition costs for the company's flagship mental health counseling platform.

  • June 20, 2025

    Ga. Panel Says Suit To Collect $12.1M Judgment Too Late

    The Georgia Court of Appeals on Friday said a trial court rightly found Mariner Healthcare Management Co.'s lawsuit against Sovereign Healthcare LLC over the recovery of a $12.1 million judgment was barred by the state's four-year statute of limitations for fraud.

  • June 20, 2025

    Taxation With Representation: Latham, Paul Weiss, Covington

    In this week's Taxation With Representation, Nippon Steel closes its purchase of U.S. Steel, Hunter Point Capital buys a minority stake in Equitix, Eaton acquires Ultra PCS Ltd. from the Cobham Ultra Group, and Eli Lilly and Co. acquires Verve Therapeutics.

  • June 18, 2025

    Ga. Panel Affirms Emory's Early Win In Neonatal Care Suit

    The Georgia Court of Appeals said a trial court rightly freed Emory Healthcare from a suit alleging that a nurse in the neonatal intensive care unit failed to spot an intravenous line infiltration that left a newborn with skin and tissue deformities.

  • June 18, 2025

    Spectrum Pharma Investors Get First OK For $16M Deal

    A Nevada federal judge has given the first green light to a nearly $16 million settlement between a pharmaceutical company and a class of investors who claimed the company and its executives overstated the status of two of its developed drugs and withheld negative data and trial results, leading to a stock drop when the truth was revealed.

  • June 18, 2025

    Attorneys Say Look Before Leaping Back Into Senior Housing

    Attorneys advising on senior housing deals are seeing more interest from investors and developers, due to demographic trends and the post-pandemic recovery, but emphasize the unique legal considerations of a sector that straddles healthcare and real estate.

  • June 18, 2025

    FDA Dodges Suit Over Ozempic, Wegovy Listing

    The U.S. Food and Drug Administration was able to escape allegations that it catered to Big Pharma by nixing cheaper versions of the miracle weight loss drug Ozempic, after a Texas federal judge tossed a lawsuit from two compounding pharmacies.

  • June 18, 2025

    InnovAge IPO Investors Get Initial OK Of $27M Settlement

    A Colorado federal judge has preliminarily approved a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior-health care company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the falsehoods.

  • June 17, 2025

    Cancer Diagnostics Firm, Insurer Price 2 IPOs Totaling $902M

    Cancer-diagnostics test provider Caris Life Sciences Inc. and coastal-focused residential insurer Slide Insurance Holdings Inc. will begin trading Wednesday after pricing two initial public offerings that raised a combined $902 million, guided by five law firms.

  • June 17, 2025

    Oregon's Corporate Ownership Law Puts PE At Crossroads

    A new law in Oregon is leaving private equity firms and other organizations at a crossroads as they try to figure out how to navigate stricter rules focused on corporate ownership of healthcare practices.

  • June 17, 2025

    Surgery Partners Rejects $3.3B Bain Offer, Eyes Public Growth

    Surgery Partners, a short-stay surgical facility owner, said on Tuesday it has ended talks with Bain Capital regarding a nearly $3.3 billion take-private proposal, saying it sees a stronger future as a public company.

  • June 17, 2025

    Kirkland-Led Lilly Inks $1.3B Deal For Cardio Drug Co. Verve

    Kirkland-advised Eli Lilly and Co. said Tuesday it will acquire Paul Weiss-advised Verve Therapeutics in a deal worth up to $1.3 billion, continuing its push into next-generation genetic medicines for heart disease.

  • June 13, 2025

    AbbVie Sues Colo. Over State Discount Drug Law

    AbbVie Inc. on Thursday filed suit in Colorado federal court seeking to block an incoming state law it alleges conflicts with the federal 340B drug discount program by forcing pharmaceutical manufacturers to sell drugs at steep discounts to commercial pharmacy chains like Walgreens and CVS.

  • June 13, 2025

    Health Tech Co. Overstated AI Capabilities, Investor Suit Says

    Health technology company Tempus AI Inc. and two of its executives face a shareholder class action over claims the company misrepresented its artificial intelligence capabilities, the value of its contracts and the credibility of certain joint ventures, among other things. 

  • June 13, 2025

    Ga. Medical Co. Accused Of Infringing Swedish Co.'s Patents

    A Swedish medical device company has sued Georgia-based MedWay Group Inc. in federal court for allegedly infringing its patents for foam dressings used in wound care and management.

  • June 12, 2025

    5 Firms Guide $1.25B BioNTech, CureVac Oncology Deal

    German biotech firm BioNTech SE said Thursday that it will acquire CureVac NV, a clinical-stage mRNA specialist, in an all-stock oncology-focused deal valuing it at about $1.25 billion and involving five legal advisers. 

  • June 11, 2025

    PepGen Faces Investor Suit Over Muscular Dystrophy Drug

    Clinical-stage biotech company PepGen Inc. has been hit with a proposed shareholder class action alleging it misled investors about the efficacy and commercial prospects of its muscular dystrophy drug, causing share price declines as investors learned of the drug's clinical trials' shortcomings.

  • June 10, 2025

    Healthcare Deals This Week: Omada, Antares, Amplify

    The healthcare industry saw a few notable deals this past week, including a much-anticipated IPO from digital health company Omada and a handful of private fundraises among startups.

  • June 10, 2025

    Ill. Judge Questions Standing In Biogen Antitrust Suit

    An Illinois federal judge seemed skeptical Tuesday that health benefit plans accusing Biogen of impairing competition for its multiple sclerosis drug, Tecfidera, have standing to bring their lawsuit under decades-old precedent allowing only direct purchasers to recoup damages.

  • June 10, 2025

    23andMe Auction Is A Wake-Up Call For Data Privacy Law

    With its giant trove of customer genetic and health data up for auction, direct-to-consumer genetic testing company 23andMe's bankruptcy is revealing glaring gaps in federal data privacy laws.

  • June 10, 2025

    Drug Cos. Face Persistent Scrutiny Over Physician Kickbacks

    Drugmakers continue to become ensnared in — and settle — investigations into illegal payments to healthcare providers for participating in sham speaker programs. These payments raise ethical questions about patient harm and whether they are seen as a cost of doing business.

  • June 09, 2025

    AI-Powered Cancer Diagnostics Firm Targets $400M IPO

    Caris Life Sciences Inc., a developer of artificial-intelligence enhanced cancer diagnostic tests, on Monday launched plans for an estimated $400 million initial public offering, represented by Latham & Watkins LLP and underwriters counsel Cooley LLP.

  • June 09, 2025

    Rite Aid Gets Stay Of Appeals From Its Earlier Bankruptcy

    The New Jersey bankruptcy judge overseeing Rite Aid's current insolvency case pressed pause Monday on appeals of orders he entered last year in the drugstore chain's previous Chapter 11.

Expert Analysis

  • SBA Proposal Materially Alters Contractor Recertification

    Author Photo

    The Small Business Administration's new proposed rule on recertification affects eligibility for set-aside contracts, significantly alters the landscape for mergers and acquisitions in the government contracts industry, and could have other unintended downstream consequences, says Sam Finnerty at PilieroMazza.

  • Firms Must Offer A Trifecta Of Services In Post-Chevron World

    Author Photo

    After the U.S. Supreme Court’s Loper Bright Enterprises v. Raimondo decision overturning Chevron deference, law firms will need to integrate litigation, lobbying and communications functions to keep up with the ramifications of the ruling and provide adequate counsel quickly, says Neil Hare at Dentons.

  • Del. Dispatch: Director Caremark Claims Need Extreme Facts

    Author Photo

    The Delaware Court of Chancery recently dismissed Caremark claims against the directors of Centene in Bricklayers Pension Fund of Western Pennsylvania v. Brinkley, indicating a high bar for a finding of the required element of bad faith for Caremark liability, and stressing the need to resist hindsight bias, say attorneys at Fried Frank.

  • PE Firms Should Prepare For Increased False Claims Scrutiny

    Author Photo

    The impact private equity firms may have over medical decisions and care is increasingly attracting potential liability under the False Claims Act and attention from states and the federal government, so investors should follow best practices including conducting due diligence both before and after acquisitions, say attorneys at K&L Gates.

  • Unpacking HHS' Opinion On Cell Therapy Refund Programs

    Author Photo

    A recent advisory opinion from the U.S. Department of Health and Human Services, determining that a biopharma company's refund program for its cell therapy will not be penalized, indicates an encouraging willingness to engage, but the regulator's assumptions about the program's limited term warrant a closer look, says Mary Kohler at Kohler Health.

  • How 5 States' Deal Notification Laws Are Guiding Healthcare

    Author Photo

    Healthcare transaction notification laws at various stages of implementation in California, Illinois, Indiana, Oregon and Washington are shaping sector mergers and acquisitions, with significant transparency, continuity of care and compliance implications as providers tackle complex regulatory requirements, says Melesa Freerks at DLA Piper.

  • The Good, The Bad And The Ugly Of Healthcare's PE Boom

    Author Photo

    While an influx of capital may provide access to new resources and innovative technologies, the private equity model's method of funding may be fundamentally at odds with patient-first healthcare, and in recent years that inherent tension has gotten ugly, say Eva Gunasekera and Jaclyn Tayabji at Tycko & Zavareei.

  • High Court Made Profound Mistake In Tossing Purdue Deal

    Author Photo

    The U.S. Supreme Court's recent decision to throw out Purdue Pharma's Chapter 11 plan jeopardizes a multistate agreement that would provide approximately $7 billion in much-needed relief to help fight the opioid epidemic, with states now likely doomed to spend years chasing individual defendants across the globe, says Swain Wood at Morningstar.

  • After Chevron: Scale Tips Favor Away From HHS Agencies

    Author Photo

    The loss of Chevron deference may indirectly aid parties in challenging the U.S. Department of Health and Human Services' interpretations of regulations and could immediately influence several pending cases challenging HHS on technical questions and agency authority, say attorneys at Ropes & Gray.

  • After Chevron: FDA Regulations In The Crosshairs

    Author Photo

    The U.S. Supreme Court's overturning of the Chevron doctrine is likely to unleash an array of challenges against the U.S. Food and Drug Administration, focusing on areas of potential overreach such as the FDA's authority under the Federal Food, Drug and Cosmetic Act, say attorneys at Debevoise.

  • Navigating Scrutiny Of Friendly Professional Corps. In Calif.

    Author Photo

    In light of ongoing scrutiny and challenges to private equity participation in the California healthcare marketplace, particularly surrounding the use of the friendly professional corporation model, management services organizations should consider implementing four best practices, say attorneys at Holland & Knight.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy considers two recent decisions from the Third and Tenth Circuits, and identifies practice tips around class action settlements and standing in securities litigation.

  • The Current State Of Healthcare Transaction Reviews In Calif.

    Author Photo

    As of April, certain healthcare transactions in California have been subject to additional notification compliance requirements, and complying with these new rules could significantly delay and discourage some deals, says Andrew Demetriou at Husch Blackwell.